Pfizer Inc. (NYSE:PFE) Shares Sold by Kovack Advisors Inc.

Kovack Advisors Inc. reduced its holdings in Pfizer Inc. (NYSE:PFE) by 8.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 96,385 shares of the biopharmaceutical company’s stock after selling 8,945 shares during the quarter. Kovack Advisors Inc.’s holdings in Pfizer were worth $2,775,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. boosted its stake in Pfizer by 10.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock valued at $3,161,261,000 after purchasing an additional 9,393,992 shares in the last quarter. Invesco Ltd. boosted its stake in shares of Pfizer by 30.9% during the 3rd quarter. Invesco Ltd. now owns 24,054,896 shares of the biopharmaceutical company’s stock worth $797,901,000 after acquiring an additional 5,678,004 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its stake in shares of Pfizer by 9.4% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 60,207,521 shares of the biopharmaceutical company’s stock worth $1,997,083,000 after acquiring an additional 5,185,453 shares in the last quarter. Bank of Nova Scotia boosted its stake in shares of Pfizer by 219.4% during the 3rd quarter. Bank of Nova Scotia now owns 5,503,983 shares of the biopharmaceutical company’s stock worth $182,567,000 after acquiring an additional 3,780,696 shares in the last quarter. Finally, Canada Pension Plan Investment Board boosted its stake in shares of Pfizer by 38.9% during the 3rd quarter. Canada Pension Plan Investment Board now owns 10,028,940 shares of the biopharmaceutical company’s stock worth $332,660,000 after acquiring an additional 2,807,846 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Up 0.5 %

NYSE PFE traded up $0.12 during trading on Friday, hitting $25.38. 46,479,102 shares of the company traded hands, compared to its average volume of 42,011,723. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $40.37. The business has a fifty day simple moving average of $26.96 and a 200 day simple moving average of $28.42. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The company has a market capitalization of $143.72 billion, a P/E ratio of 70.50, a PEG ratio of 1.18 and a beta of 0.61.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. During the same period last year, the business posted $1.14 earnings per share. The firm’s revenue was down 41.3% compared to the same quarter last year. As a group, sell-side analysts predict that Pfizer Inc. will post 2.24 EPS for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be given a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 6.62%. The ex-dividend date is Thursday, May 9th. Pfizer’s dividend payout ratio (DPR) is presently 466.67%.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on PFE shares. TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price for the company. in a research report on Thursday, January 4th. Argus cut Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Guggenheim started coverage on Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research report on Monday, April 15th. Eleven analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $36.33.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.